Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
1
Nicotinamide riboside-amino acid conjugates that are stable to purine nucleoside phosphorylase Faisal Hayat and Marie E. Migaud*
Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Ave., Mobile, AL 36604, USA
Supplementary
1. Copies of 1H NMR, 13C NMR, 19F-NMR and HRMS Spectra…………………………………..…………………....2-58 2. Enzymatic assays by 1H NMR…………………………………………………………………………………… …59-61 3. Table of Vorbrüggen reaction outcomes…………………………………………………………………………………62
Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry.This journal is © The Royal Society of Chemistry 2020
2
Compound 4. 400 MHz 1H NMR spectrum in Acetone-d6
3
Compound 4. 100 MHz 13C NMR spectrum in Acetone-d6
4
Compound 7. 400 MHz 1H NMR spectrum in D2O
5
Compound 7. 100 MHz 13C NMR spectrum in D2O
6
Compound 7. HRMS spectra
mm_072018_fh_01_20_1 #242-260 RT: 3.83-4.11 AV: 19 NL: 5.55E6F: FTMS + p ESI Full ms [120.00-800.00]
130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100R
elat
ive
Abu
ndan
ce
123.05448R=118611
z=1
295.12793R=77190
z=1
173.08005R=102998
z=1
141.95781R=113872
z=1
7
Compound 8. 400 MHz 1H NMR spectrum in D2O
8
Compound 8. 100 MHz 13C NMR spectrum in D2O
9
Compound 8. HRMS spectra
mm_072018_fh_01_22_1 #244-267 RT: 3.86-4.21 AV: 24 NL: 5.74E6F: FTMS + p ESI Full ms [120.00-800.00]
130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100R
elat
ive
Abun
danc
e297.14359R=77139
z=1
123.05456R=119611
z=1
141.95786R=114498
z=1
173.08007R=103770
z=1
10
Compound 10a. 400 MHz 1H NMR spectrum in MeOD
11
Compound 10a. 100 MHz 13C NMR spectrum in MeOD
12
Compound 10a. HRMS spectra
mm_101618_nrh_glycine_01 #17-31 RT: 0.25-0.46 AV: 15 SB: 81 5.79-7.06 NL: 1.49E7F: FTMS + p ESI Full ms [200.00-1050.00]
450 451 452 453 454 455 456 457 458m/z
0
10
20
30
40
50
60
70
80
90
100
Rel
ativ
e A
bund
ance
454.2186R=60354
z=1C 28 H30 N4 S-0.0052 ppm
C 21 H32 O8 N30.3863 ppm
452.2033R=59378
z=1C 14 H30 O6 N9 S
-0.3233 ppmC 15 H36 O11 N2 S
-0.3348 ppm
455.2218R=61699
z=1C 15 H35 O4 N8 S 2
0.1158 ppmC 30 H31 O40.1895 ppm
13
Compound 10b. 400 MHz 1H NMR spectrum in MeOD
14
Compound 10b. 100 MHz 13C NMR spectrum in MeOD
15
Compound 10b. HRMS spectra
mm_101618_nrh_leucine_01 #17-32 RT: 0.25-0.47 AV: 16 SB: 81 5.78-7.05 NL: 2.10E7F: FTMS + p ESI Full ms [200.00-1050.00]
507 508 509 510 511 512 513m/z
0
20
40
60
80
100
Rel
ativ
e A
bund
ance
510.2817R=57440
z=1C 26 H36 O4 N7-0.6538 mmuC 27 H42 O9-0.6590 mmu
C 25 H40 O8 N30.6837 mmu
508.2663R=56874
z=1C 26 H34 O4 N7-0.4031 mmuC 27 H40 O9-0.4082 mmu
C 25 H38 O8 N30.9344 mmu
511.2848R=57516
z=1C 20 H41 O10 N5
0.0095 mmuC 21 H37 O6 N9-1.3280 mmu
C 22 H43 O11 N2-1.3331 mmu
509.2696R=56261
z=?C 20 H39 O10 N5
0.4321 mmuC 21 H35 O6 N9-0.9054 mmu
C 22 H41 O11 N2-0.9106 mmu
16
Compound 10c. 400 MHz 1H NMR spectrum in MeOD
17
Compound 10c. 100 MHz 13C NMR spectrum in MeOD
18
Compound 10c. HRMS spectra
mm_101618_nrh_valine_01 #16-30 RT: 0.23-0.44 AV: 15 SB: 81 5.78-7.06 NL: 1.51E7F: FTMS + p ESI Full ms [200.00-1050.00]
493 494 495 496 497 498m/z
0
10
20
30
40
50
60
70
80
90
100
Rel
ativ
e A
bund
ance
496.2657R=58296
z=1C 24 H38 O8 N3
0.3563 mmu
494.2505R=58700
z=1C 25 H32 O4 N7-0.5448 mmu
497.2691R=58231
z=1C 19 H39 O10 N5
-0.0212 mmu
495.2542R=58360
z=?C 20 H33 O6 N9-0.6596 mmu
19
Compound 10d. 400 MHz 1H NMR spectrum in MeOD
20
Compound 10d. 100 MHz 13C NMR spectrum in MeOD
21
Compound 10d. HRMS spectra
mm_101618_nrh_tryptophan_01 #17-41 RT: 0.25-0.61 AV: 25 SB: 81 5.78-7.06 NL: 2.03E7F: FTMS + p ESI Full ms [200.00-1050.00]
680 681 682 683 684 685 686 687 688m/z
0
10
20
30
40
50
60
70
80
90
100
Rel
ativ
e A
bund
ance
683.3276R=50853
z=1
684.3305R=50849
z=1
681.3123R=50150
z=1685.3333R=51048
z=1682.3158R=50741
z=?
22
Compound 10e. 400 MHz 1H NMR spectrum in MeOD
23
Compound 10e. 100 MHz 13C NMR spectrum in MeOD
24
Compound 10e. HRMS spectra
mm_072219_nrh_phenylalanine_1 #5-28 RT: 0.07-0.26 AV: 8 NL: 2.55E7F: FTMS + p ESI Full ms [100.00-600.00]
540 541 542 543 544 545 546 547 548 549m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Rel
ativ
e A
bund
ance
544.26593R=56245
z=1
545.26919R=55336
z=1
542.25069R=56007
z=1
543.25400R=56282
z=1
546.27201R=57569
z=1
25
Compound 10f. 400 MHz 1H NMR spectrum in MeOD
26
Compound 10f. 100 MHz 13C NMR spectrum in MeOD
27
Compound 10f. HRMS spectra
mm_101618_nrh_isoleucine_01 #17-33 RT: 0.25-0.49 AV: 17 SB: 81 5.78-7.06 NL: 2.47E7F: FTMS + p ESI Full ms [200.00-1050.00]
507 508 509 510 511 512 513 514m/z
0
20
40
60
80
100
Rel
ativ
e A
bund
ance
510.2821R=56884
z=1C 26 H36 O4 N7
-0.4491 ppmC 27 H42 O9-0.4593 ppm
C 25 H40 O8 N32.1720 ppm
511.2851R=56955
z=1C 20 H41 O10 N5
0.6638 ppmC 21 H37 O6 N9
-1.9522 ppmC 22 H43 O11 N2
-1.9623 ppm
508.2667R=57549
z=1C 27 H40 O90.0774 ppm
C 26 H34 O4 N70.0876 ppm
C 28 H36 O5 N4-2.5540 ppm
509.2700R=57198
z=?C 21 H35 O6 N9
-0.9270 ppmC 22 H41 O11 N2
-0.9372 ppmC 20 H39 O10 N5
1.6993 ppm
28
Compound 10g. 400 MHz 1H NMR spectrum in MeOD
29
Compound 10g. 100 MHz 13C NMR spectrum in MeOD
30
Compound 10g. HRMS spectra
mm_101618_nrh_methionine_01 #18-32 RT: 0.26-0.47 AV: 15 SB: 81 5.78-7.06 NL: 2.46E7F: FTMS + p ESI Full ms [200.00-1050.00]
525 526 527 528 529 530 531m/z
0
10
20
30
40
50
60
70
80
90
100R
elat
ive
Abu
ndan
ce
528.2387R=56309
z=1
529.2419R=56244
z=1
526.2235R=55989
z=1
31
Compound 12a. 400 MHz 1H NMR spectrum in D2O
32
Compound 12a. 100 MHz 13C NMR spectrum in D2O
33
Compound 12a. 377 MHz 19F NMR spectrum in MeOD
34
Compound 12a. HRMS spectra
mm_101618_nr_glycine_01 #13-21 RT: 0.18-0.31 AV: 9 SB: 82 5.78-7.07 NL: 2.79E6F: FTMS + p ESI Full ms [200.00-1050.00]
305 310 315 320m/z
0
20
40
60
80
100
Rel
ativ
e Ab
unda
nce
312.1197R=73560
z=1C 14 H14 O 2 N7
-1.9392 ppmC 15 H20 O 7-1.9558 ppm
C 13 H18 O 6 N32.3460 ppm
313.1230R=74186
z=1C 8 H19 O 8 N5
0.7378 ppmC 22 H17 O 22.3591 ppm
C 9 H15 O 4 N9-3.5336 ppm
35
Compound 12b. 400 MHz 1H NMR spectrum in D2O
36
Compound 12b. 100 MHz 13C NMR spectrum in D2O
37
Compound 12b. 377 MHz 19F NMR spectrum in MeOD
38
Compound 12b. HRMS spectra
mm_101618_nr_leucine_01 #13-22 RT: 0.18-0.32 AV: 10 SB: 82 5.78-7.06 NL: 4.94E6F: FTMS + p ESI Full ms [200.00-1050.00]
366 367 368 369 370 371 372m/z
0
10
20
30
40
50
60
70
80
90
100
Rel
ativ
e Ab
unda
nce
368.1816R=67557
z=1C 16 H20 O N10
-0.1071 ppmC 17 H26 O 6 N3
-0.1212 ppm
369.1849R=66613
z=1C 26 H25 O 2
0.0990 ppmC 12 H27 O 8 N5-1.2761 ppm
39
Compound 12c. 400 MHz 1H NMR spectrum in D2O
40
Compound 12c. 100 MHz 13C NMR spectrum in D2O
41
Compound 12c. 377 MHz 19F NMR spectrum in MeOD
42
Compound 12c. HRMS spectra
mm_101618_nr_valine_01 #13-44 RT: 0.18-0.65 AV: 32 SB: 82 5.77-7.06 NL: 1.32E6F: FTMS + p ESI Full ms [200.00-1050.00]
352 353 354 355 356 357m/z
0
10
20
30
40
50
60
70
80
90
100R
elat
ive
Abun
danc
e
354.1661R=69575
z=1C 16 H24 O 6 N3
0.3722 ppm
355.1695R=67522
z=1C 25 H23 O 2
0.6424 ppm
43
Compound 12d. 400 MHz 1H NMR spectrum in D2O
44
Compound 12d. 100 MHz 13C NMR spectrum in D2O
45
Compound 12d. 377 MHz 19F NMR spectrum in MeOD
46
Compound 12d. HRMS spectra
mm_101618_nr_tryptophan_01 #13-21 RT: 0.18-0.31 AV: 9 SB: 82 5.78-7.07 NL: 7.47E5F: FTMS + p ESI Full ms [200.00-1050.00]
438 439 440 441 442 443 444 445 446m/z
0
10
20
30
40
50
60
70
80
90
100
Rel
ativ
e Ab
unda
nce
441.1773R=61755
z=1C 8 H27 O 12 N9
-0.2166 ppmC 22 H25 O 6 N4
0.9341 ppm
442.1805R=61373
z=1C 17 H26 O 8 N6
-0.3455 ppmC 16 H30 O 12 N2
2.6793 ppm
47
Compound 12e. 400 MHz 1H NMR spectrum in D2O
48
Compound 12e. 100 MHz 13C NMR spectrum in D2O
49
Compound 12e. 377 MHz 19F NMR spectrum in MeOD
50
Compound 12e. HRMS spectra
mm_101618_nr_phenylalanine_01 #13-23 RT: 0.18-0.33 AV: 11 SB: 82 5.77-7.06 NL: 4.94E6F: FTMS + p ESI Full ms [200.00-1050.00]
399 400 401 402 403 404 405 406 407m/z
0
10
20
30
40
50
60
70
80
90
100
Rel
ativ
e Ab
unda
nce
402.1663R=64928
z=1C 20 H24 O 6 N3
0.8076 ppm
403.1696R=63979
z=1C 15 H25 O 8 N5
-0.4827 ppm
51
Compound 12f. 400 MHz 1H NMR spectrum in D2O
52
Compound 12f. 100 MHz 13C NMR spectrum in D2O
53
Compound 12f. 377 MHz 19F NMR spectrum in MeOD
54
Compound 12f. HRMS spectra
mm_101618_nr_isoleucine_01 #13-24 RT: 0.18-0.35 AV: 12 SB: 82 5.78-7.07 NL: 4.58E6F: FTMS + p ESI Full ms [200.00-1050.00]
366 367 368 369 370 371m/z
0
10
20
30
40
50
60
70
80
90
100
Rel
ativ
e Ab
unda
nce
368.1820R=68181
z=1C 17 H26 O 6 N3
0.9686 ppm
369.1854R=65044
z=1C 12 H27 O 8 N5
-0.1098 ppm
55
Compound 12g. 400 MHz 1H NMR spectrum in D2O
56
Compound 12g. 100 MHz 13C NMR spectrum in D2O
57
Compound 12g. 377 MHz 19F NMR spectrum in MeOD
58
Compound 12g. HRMS spectra
mm_101618_nr_methionine_01 #12-22 RT: 0.17-0.32 AV: 11 SB: 81 5.78-7.05 NL: 2.48E6F: FTMS + p ESI Full ms [200.00-1050.00]
384 385 386 387 388 389 390m/z
0
10
20
30
40
50
60
70
80
90
100R
elat
ive
Abu
ndan
ce
386.1376R=65949
z=1
387.1410R=64324
z=1
59
* Nicotinamide riboside ∆ Nicotinamide ● D-Ribose-1-phosphate
** **
*
** **
*
* * *
** * **
**
** *
* * **
60
† NR-glycine * Nicotinamide riboside
61
OH OH
N +
N H 2O
OOH N H 3
+
O
O–
NH2
O
NO HOH
O H
O –O
POO
OHO HOH
O NH2
N+OO
NH2
O
GlycineNR
D-Ribose-1-phosphateNAM
0-6 hoursPNP, HEPES H2PO4- ,
NR-Glycine
+
+
† NR-glycine ∆ Nicotinamide ● D-Ribose-1-phosphate Detailed PNP enzyme activity assay. The phosphorolysis of nicotinamide riboside chloride (NR-Cl) and glycine nicotinamide riboside conjugate (Gly-NR) catalyzed by PNP (Purine Nucleoside Phosphorylase) was performed at room temperature and monitored by 1H NMR at t = 0, 20 min and 6 h. All one dimensional spectra were obtained at 300 K on a Bruker AscendTM 400 MHz ultrashielded spectrometer (Bruker Biospin) operating at 400.13 MHz for protons (9.39 Tesla). TopSpin 3.2 (Bruker BioSpin) was used for all NMR spectral acquisition (ns=128) and pre-processing, and the automation of sample submission was performed using ICON-NMR (Bruker BioSpin). All samples were automatically shimmed, and the spectra acquisition time was 10 minutes 08 seconds (ns=128). Each NMR tube (7inch x 5mm) contained 450 µl HEPES buffer (100.0 mM, pH 7.0) which included 100 mM KH2PO4, 5 µl PNP (1mg dissolved in 50µl HEPES buffer), 50.0 µl NR-Cl and NR glycine conjugate (50.0 mM in 1 mL D2O). For each independent experiment used freshly prepared solutions of NR-Cl and NR glycine conjugate in HEPES buffer, containing 100 mM KH2PO4 (13.6 mg/mL) and 50 µl D2O.
62
TABLE 1: exploratory conditions for the synthesis of NR amino acid conjugate 5 by ball-milling.
Entry
TMSOTf
Solvent
Reaction outcomes a,b
1 1 eqv 2 eqv DCE (1 eqv) trace 2 1 eqv 2 eqv DCE (1eqv) trace 3 1 eqv 0.5 eqv DCM (1 eqv) trace 4 1 eqv 1 eqv CH3CN (1 eqv) trace 5 1 eqv 2 eqv CH3CN (3 eqv) trace 6 1 eqv 3 eqv CH3CN (5 eqv) trace
a ball-milling (30Hz), 30 minutes; b crude 1H-NMR indicated decomposition of the riboside and formation of trace quantities of the expected product, product formation was confirmed by
MS.